No Fee Unless We Win:

Pharmaceutical Company Connected to NDMA Impurity Placed on Import Alert

Active pharmaceutical ingredient (API) manufacturer Zhejiang Huahai Pharmaceuticals was placed on import alert on Friday, September 28 by the U.S. Food and Drug Administration (FDA). The company will determine how its products, used in valsartan-containing drug products became affected by N-nitrosodimethylamine (NDMA).

The FDA has been updating its list of valsartan products under recall, which can be found here (accurate as of September 28, 2018) (PDF).

“We have carefully assessed the valsartan-containing medications sold in the United States, and we’ve found that the valsartan sold by these specific companies does not meet our safety standards. This is why we’ve asked these companies to take immediate action to protect patients,” said Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research when the recall was first announced.

If you or someone you love was seriously affected by tainted medication or defective drugs, our Houston personal injury lawyers at Bailey Peavy Bailey Cowan Heckaman are ready to provide you with the legal support you need. Give our firm a call to discuss your situation today, or send us the details of your situation through our online form and a member of our staff will reach out to you as soon as possible to set up a free consultation. Don’t wait to get the help you need, contact Bailey Cowan Heckaman PLLC today.

Related Posts:

Share This Story
If you found this article helpful your friends might too! Please consider sharing this story to your social media channels by tapping the buttons below. 
Begin Your Journey to Justice Today

No Fee Unless We Win:
Quick Links
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram